INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15701, 0, 'Perampanel', 'Hepatic Insufficiency', 'The use of perampanel in patients with severe hepatic impairment is not recommended.  Dosage adjustments are recommended in patients with mild or moderate hepatic impairment as the half-life of perampanel may increase in these patients.  Care should be exercised when prescribing this agent to patients with hepatic impairment, and close monitoring of liver function is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15702, 0, 'Pergolide', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15703, 0, 'Pergolide', 'Neuroleptic Malignant Syndrome', 'The use of dopamine agonists is contraindicated in patients with neuroleptic malignant syndrome (NMS).  NMS is characterized by hyperthermia, muscle rigidity, altered mental status, irregular pulse or blood pressure, tachycardia, and diaphoresis.  The syndrome may rarely be precipitated by abrupt discontinuation of the dopamine agonist.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15704, 0, 'Pergolide', 'Psychotic Disorders', 'The use of dopamine agonists has been associated with psychiatric effects such as hallucinations, psychosis, confusion, anxiety, mania, hypomania, depression, rapid mood cycling, nightmares, and hypersexuality.  Therapy with dopamine agonists should be administered cautiously in psychotic patients and all patients should be carefully observed for development of depression and suicidal tendencies.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15705, 0, 'Pergolide', 'Heart Valve Diseases', 'The use of pergolide has been shown to increase the risk of cardiac valvular disease involving one or more valves.  Some patients have required valve replacement, and deaths have been reported.  Specific risk factors predisposing patients to developing cardiac valvular disease with pergolide have not been identified.  Cardiac valvulopathy has been reported with all doses of pergolide; however, available data suggest that the risk may be greater with higher doses.  Pergolide is not recommended for use in patients with a history of cardiac valvulopathy.  Additionally, caution should be exercised when administering pergolide to patients prone to cardiac dysrhythmias.  Before initiating treatment with pergolide, all patients should undergo a cardiovascular evaluation, including an echocardiogram, to determine whether valvular disease is present and to provide a baseline for subsequent monitoring.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15706, 9007, 'Pentoxifylline', 'Cerebral Hemorrhage', 'The use of pentoxifylline is contraindicated in patients with recent cerebral and/or retinal hemorrhage.  Dose-related hemorrhagic effects can occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15707, 9729, 'Pentoxifylline', 'Cerebral Hemorrhage', 'The use of pentoxifylline is contraindicated in patients with recent cerebral and/or retinal hemorrhage.  Dose-related hemorrhagic effects can occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15708, 11607, 'Pentoxifylline', 'Cerebral Hemorrhage', 'The use of pentoxifylline is contraindicated in patients with recent cerebral and/or retinal hemorrhage.  Dose-related hemorrhagic effects can occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15709, 11608, 'Pentoxifylline', 'Cerebral Hemorrhage', 'The use of pentoxifylline is contraindicated in patients with recent cerebral and/or retinal hemorrhage.  Dose-related hemorrhagic effects can occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15710, 12106, 'Pentoxifylline', 'Cerebral Hemorrhage', 'The use of pentoxifylline is contraindicated in patients with recent cerebral and/or retinal hemorrhage.  Dose-related hemorrhagic effects can occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15711, 12107, 'Pentoxifylline', 'Cerebral Hemorrhage', 'The use of pentoxifylline is contraindicated in patients with recent cerebral and/or retinal hemorrhage.  Dose-related hemorrhagic effects can occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15712, 24699, 'Pentoxifylline', 'Cerebral Hemorrhage', 'The use of pentoxifylline is contraindicated in patients with recent cerebral and/or retinal hemorrhage.  Dose-related hemorrhagic effects can occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15713, 24700, 'Pentoxifylline', 'Cerebral Hemorrhage', 'The use of pentoxifylline is contraindicated in patients with recent cerebral and/or retinal hemorrhage.  Dose-related hemorrhagic effects can occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15714, 24780, 'Pentoxifylline', 'Cerebral Hemorrhage', 'The use of pentoxifylline is contraindicated in patients with recent cerebral and/or retinal hemorrhage.  Dose-related hemorrhagic effects can occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15715, 25745, 'Pentoxifylline', 'Cerebral Hemorrhage', 'The use of pentoxifylline is contraindicated in patients with recent cerebral and/or retinal hemorrhage.  Dose-related hemorrhagic effects can occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15716, 25746, 'Pentoxifylline', 'Cerebral Hemorrhage', 'The use of pentoxifylline is contraindicated in patients with recent cerebral and/or retinal hemorrhage.  Dose-related hemorrhagic effects can occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15717, 25747, 'Pentoxifylline', 'Cerebral Hemorrhage', 'The use of pentoxifylline is contraindicated in patients with recent cerebral and/or retinal hemorrhage.  Dose-related hemorrhagic effects can occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15718, 28435, 'Pentoxifylline', 'Cerebral Hemorrhage', 'The use of pentoxifylline is contraindicated in patients with recent cerebral and/or retinal hemorrhage.  Dose-related hemorrhagic effects can occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15719, 29020, 'Pentoxifylline', 'Cerebral Hemorrhage', 'The use of pentoxifylline is contraindicated in patients with recent cerebral and/or retinal hemorrhage.  Dose-related hemorrhagic effects can occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15720, 29029, 'Pentoxifylline', 'Cerebral Hemorrhage', 'The use of pentoxifylline is contraindicated in patients with recent cerebral and/or retinal hemorrhage.  Dose-related hemorrhagic effects can occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15721, 31554, 'Pentoxifylline', 'Cerebral Hemorrhage', 'The use of pentoxifylline is contraindicated in patients with recent cerebral and/or retinal hemorrhage.  Dose-related hemorrhagic effects can occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15722, 9007, 'Pentoxifylline', 'Cardiomyopathies', 'Although pentoxifylline has been used safely to treat peripheral arterial disease in patients with concurrent coronary artery and cerebrovascular diseases, there have been occasional reports of angina, arrhythmia, and hypotension.  Controlled trials do not show a causal relationship; however, since pentoxifylline is a methylxanthine derivative, the possibility of these adverse effects should be considered.  Therapy with pentoxifylline should be administered cautiously in patients with arrhythmia, coronary artery and/or cerebrovascular insufficiency.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15723, 9729, 'Pentoxifylline', 'Cardiomyopathies', 'Although pentoxifylline has been used safely to treat peripheral arterial disease in patients with concurrent coronary artery and cerebrovascular diseases, there have been occasional reports of angina, arrhythmia, and hypotension.  Controlled trials do not show a causal relationship; however, since pentoxifylline is a methylxanthine derivative, the possibility of these adverse effects should be considered.  Therapy with pentoxifylline should be administered cautiously in patients with arrhythmia, coronary artery and/or cerebrovascular insufficiency.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15724, 11607, 'Pentoxifylline', 'Cardiomyopathies', 'Although pentoxifylline has been used safely to treat peripheral arterial disease in patients with concurrent coronary artery and cerebrovascular diseases, there have been occasional reports of angina, arrhythmia, and hypotension.  Controlled trials do not show a causal relationship; however, since pentoxifylline is a methylxanthine derivative, the possibility of these adverse effects should be considered.  Therapy with pentoxifylline should be administered cautiously in patients with arrhythmia, coronary artery and/or cerebrovascular insufficiency.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15725, 11608, 'Pentoxifylline', 'Cardiomyopathies', 'Although pentoxifylline has been used safely to treat peripheral arterial disease in patients with concurrent coronary artery and cerebrovascular diseases, there have been occasional reports of angina, arrhythmia, and hypotension.  Controlled trials do not show a causal relationship; however, since pentoxifylline is a methylxanthine derivative, the possibility of these adverse effects should be considered.  Therapy with pentoxifylline should be administered cautiously in patients with arrhythmia, coronary artery and/or cerebrovascular insufficiency.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15726, 12106, 'Pentoxifylline', 'Cardiomyopathies', 'Although pentoxifylline has been used safely to treat peripheral arterial disease in patients with concurrent coronary artery and cerebrovascular diseases, there have been occasional reports of angina, arrhythmia, and hypotension.  Controlled trials do not show a causal relationship; however, since pentoxifylline is a methylxanthine derivative, the possibility of these adverse effects should be considered.  Therapy with pentoxifylline should be administered cautiously in patients with arrhythmia, coronary artery and/or cerebrovascular insufficiency.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15727, 12107, 'Pentoxifylline', 'Cardiomyopathies', 'Although pentoxifylline has been used safely to treat peripheral arterial disease in patients with concurrent coronary artery and cerebrovascular diseases, there have been occasional reports of angina, arrhythmia, and hypotension.  Controlled trials do not show a causal relationship; however, since pentoxifylline is a methylxanthine derivative, the possibility of these adverse effects should be considered.  Therapy with pentoxifylline should be administered cautiously in patients with arrhythmia, coronary artery and/or cerebrovascular insufficiency.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15728, 24699, 'Pentoxifylline', 'Cardiomyopathies', 'Although pentoxifylline has been used safely to treat peripheral arterial disease in patients with concurrent coronary artery and cerebrovascular diseases, there have been occasional reports of angina, arrhythmia, and hypotension.  Controlled trials do not show a causal relationship; however, since pentoxifylline is a methylxanthine derivative, the possibility of these adverse effects should be considered.  Therapy with pentoxifylline should be administered cautiously in patients with arrhythmia, coronary artery and/or cerebrovascular insufficiency.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15729, 24700, 'Pentoxifylline', 'Cardiomyopathies', 'Although pentoxifylline has been used safely to treat peripheral arterial disease in patients with concurrent coronary artery and cerebrovascular diseases, there have been occasional reports of angina, arrhythmia, and hypotension.  Controlled trials do not show a causal relationship; however, since pentoxifylline is a methylxanthine derivative, the possibility of these adverse effects should be considered.  Therapy with pentoxifylline should be administered cautiously in patients with arrhythmia, coronary artery and/or cerebrovascular insufficiency.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15730, 24780, 'Pentoxifylline', 'Cardiomyopathies', 'Although pentoxifylline has been used safely to treat peripheral arterial disease in patients with concurrent coronary artery and cerebrovascular diseases, there have been occasional reports of angina, arrhythmia, and hypotension.  Controlled trials do not show a causal relationship; however, since pentoxifylline is a methylxanthine derivative, the possibility of these adverse effects should be considered.  Therapy with pentoxifylline should be administered cautiously in patients with arrhythmia, coronary artery and/or cerebrovascular insufficiency.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15731, 25745, 'Pentoxifylline', 'Cardiomyopathies', 'Although pentoxifylline has been used safely to treat peripheral arterial disease in patients with concurrent coronary artery and cerebrovascular diseases, there have been occasional reports of angina, arrhythmia, and hypotension.  Controlled trials do not show a causal relationship; however, since pentoxifylline is a methylxanthine derivative, the possibility of these adverse effects should be considered.  Therapy with pentoxifylline should be administered cautiously in patients with arrhythmia, coronary artery and/or cerebrovascular insufficiency.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15732, 25746, 'Pentoxifylline', 'Cardiomyopathies', 'Although pentoxifylline has been used safely to treat peripheral arterial disease in patients with concurrent coronary artery and cerebrovascular diseases, there have been occasional reports of angina, arrhythmia, and hypotension.  Controlled trials do not show a causal relationship; however, since pentoxifylline is a methylxanthine derivative, the possibility of these adverse effects should be considered.  Therapy with pentoxifylline should be administered cautiously in patients with arrhythmia, coronary artery and/or cerebrovascular insufficiency.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15733, 25747, 'Pentoxifylline', 'Cardiomyopathies', 'Although pentoxifylline has been used safely to treat peripheral arterial disease in patients with concurrent coronary artery and cerebrovascular diseases, there have been occasional reports of angina, arrhythmia, and hypotension.  Controlled trials do not show a causal relationship; however, since pentoxifylline is a methylxanthine derivative, the possibility of these adverse effects should be considered.  Therapy with pentoxifylline should be administered cautiously in patients with arrhythmia, coronary artery and/or cerebrovascular insufficiency.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15734, 28435, 'Pentoxifylline', 'Cardiomyopathies', 'Although pentoxifylline has been used safely to treat peripheral arterial disease in patients with concurrent coronary artery and cerebrovascular diseases, there have been occasional reports of angina, arrhythmia, and hypotension.  Controlled trials do not show a causal relationship; however, since pentoxifylline is a methylxanthine derivative, the possibility of these adverse effects should be considered.  Therapy with pentoxifylline should be administered cautiously in patients with arrhythmia, coronary artery and/or cerebrovascular insufficiency.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15735, 29020, 'Pentoxifylline', 'Cardiomyopathies', 'Although pentoxifylline has been used safely to treat peripheral arterial disease in patients with concurrent coronary artery and cerebrovascular diseases, there have been occasional reports of angina, arrhythmia, and hypotension.  Controlled trials do not show a causal relationship; however, since pentoxifylline is a methylxanthine derivative, the possibility of these adverse effects should be considered.  Therapy with pentoxifylline should be administered cautiously in patients with arrhythmia, coronary artery and/or cerebrovascular insufficiency.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15736, 29029, 'Pentoxifylline', 'Cardiomyopathies', 'Although pentoxifylline has been used safely to treat peripheral arterial disease in patients with concurrent coronary artery and cerebrovascular diseases, there have been occasional reports of angina, arrhythmia, and hypotension.  Controlled trials do not show a causal relationship; however, since pentoxifylline is a methylxanthine derivative, the possibility of these adverse effects should be considered.  Therapy with pentoxifylline should be administered cautiously in patients with arrhythmia, coronary artery and/or cerebrovascular insufficiency.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15737, 31554, 'Pentoxifylline', 'Cardiomyopathies', 'Although pentoxifylline has been used safely to treat peripheral arterial disease in patients with concurrent coronary artery and cerebrovascular diseases, there have been occasional reports of angina, arrhythmia, and hypotension.  Controlled trials do not show a causal relationship; however, since pentoxifylline is a methylxanthine derivative, the possibility of these adverse effects should be considered.  Therapy with pentoxifylline should be administered cautiously in patients with arrhythmia, coronary artery and/or cerebrovascular insufficiency.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15738, 9007, 'Pentoxifylline', 'Hepatic Insufficiency', 'In patients with hepatic or renal impairment, the exposure to pentoxifylline and/or active metabolites is increased.  The consequences of the increase in drug exposure are not known.  Caution is advised.  Care should be taken in dose selection, and it may be useful to monitor renal and hepatic function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15739, 9729, 'Pentoxifylline', 'Hepatic Insufficiency', 'In patients with hepatic or renal impairment, the exposure to pentoxifylline and/or active metabolites is increased.  The consequences of the increase in drug exposure are not known.  Caution is advised.  Care should be taken in dose selection, and it may be useful to monitor renal and hepatic function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15740, 11607, 'Pentoxifylline', 'Hepatic Insufficiency', 'In patients with hepatic or renal impairment, the exposure to pentoxifylline and/or active metabolites is increased.  The consequences of the increase in drug exposure are not known.  Caution is advised.  Care should be taken in dose selection, and it may be useful to monitor renal and hepatic function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15741, 11608, 'Pentoxifylline', 'Hepatic Insufficiency', 'In patients with hepatic or renal impairment, the exposure to pentoxifylline and/or active metabolites is increased.  The consequences of the increase in drug exposure are not known.  Caution is advised.  Care should be taken in dose selection, and it may be useful to monitor renal and hepatic function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15742, 12106, 'Pentoxifylline', 'Hepatic Insufficiency', 'In patients with hepatic or renal impairment, the exposure to pentoxifylline and/or active metabolites is increased.  The consequences of the increase in drug exposure are not known.  Caution is advised.  Care should be taken in dose selection, and it may be useful to monitor renal and hepatic function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15743, 12107, 'Pentoxifylline', 'Hepatic Insufficiency', 'In patients with hepatic or renal impairment, the exposure to pentoxifylline and/or active metabolites is increased.  The consequences of the increase in drug exposure are not known.  Caution is advised.  Care should be taken in dose selection, and it may be useful to monitor renal and hepatic function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15744, 24699, 'Pentoxifylline', 'Hepatic Insufficiency', 'In patients with hepatic or renal impairment, the exposure to pentoxifylline and/or active metabolites is increased.  The consequences of the increase in drug exposure are not known.  Caution is advised.  Care should be taken in dose selection, and it may be useful to monitor renal and hepatic function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15745, 24700, 'Pentoxifylline', 'Hepatic Insufficiency', 'In patients with hepatic or renal impairment, the exposure to pentoxifylline and/or active metabolites is increased.  The consequences of the increase in drug exposure are not known.  Caution is advised.  Care should be taken in dose selection, and it may be useful to monitor renal and hepatic function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15746, 24780, 'Pentoxifylline', 'Hepatic Insufficiency', 'In patients with hepatic or renal impairment, the exposure to pentoxifylline and/or active metabolites is increased.  The consequences of the increase in drug exposure are not known.  Caution is advised.  Care should be taken in dose selection, and it may be useful to monitor renal and hepatic function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15747, 25745, 'Pentoxifylline', 'Hepatic Insufficiency', 'In patients with hepatic or renal impairment, the exposure to pentoxifylline and/or active metabolites is increased.  The consequences of the increase in drug exposure are not known.  Caution is advised.  Care should be taken in dose selection, and it may be useful to monitor renal and hepatic function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15748, 25746, 'Pentoxifylline', 'Hepatic Insufficiency', 'In patients with hepatic or renal impairment, the exposure to pentoxifylline and/or active metabolites is increased.  The consequences of the increase in drug exposure are not known.  Caution is advised.  Care should be taken in dose selection, and it may be useful to monitor renal and hepatic function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15749, 25747, 'Pentoxifylline', 'Hepatic Insufficiency', 'In patients with hepatic or renal impairment, the exposure to pentoxifylline and/or active metabolites is increased.  The consequences of the increase in drug exposure are not known.  Caution is advised.  Care should be taken in dose selection, and it may be useful to monitor renal and hepatic function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15750, 28435, 'Pentoxifylline', 'Hepatic Insufficiency', 'In patients with hepatic or renal impairment, the exposure to pentoxifylline and/or active metabolites is increased.  The consequences of the increase in drug exposure are not known.  Caution is advised.  Care should be taken in dose selection, and it may be useful to monitor renal and hepatic function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15751, 29020, 'Pentoxifylline', 'Hepatic Insufficiency', 'In patients with hepatic or renal impairment, the exposure to pentoxifylline and/or active metabolites is increased.  The consequences of the increase in drug exposure are not known.  Caution is advised.  Care should be taken in dose selection, and it may be useful to monitor renal and hepatic function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15752, 29029, 'Pentoxifylline', 'Hepatic Insufficiency', 'In patients with hepatic or renal impairment, the exposure to pentoxifylline and/or active metabolites is increased.  The consequences of the increase in drug exposure are not known.  Caution is advised.  Care should be taken in dose selection, and it may be useful to monitor renal and hepatic function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15753, 31554, 'Pentoxifylline', 'Hepatic Insufficiency', 'In patients with hepatic or renal impairment, the exposure to pentoxifylline and/or active metabolites is increased.  The consequences of the increase in drug exposure are not known.  Caution is advised.  Care should be taken in dose selection, and it may be useful to monitor renal and hepatic function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15754, 0, 'Avatrombopag', 'Kidney Failure, Chronic', 'The effect of severe renal impairment (CrCl < 30 mL/min) including patients requiring hemodialysis on avatrombopag pharmacokinetics is unknown.  Caution and monitoring is advised.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15755, 0, 'Avatrombopag', 'Thromboembolism', 'Thromboembolic complications may result from increases in platelet counts with TPO receptor agonists such as avatrombopag, lusutrombopag, and eltrombopag.  Consider the potential for increased risk of thromboembolism when administering these medications to patients with known risk factors for thromboembolism, including genetic prothrombotic conditions (Factor V Leiden, Prothrombin 20210 A, Antithrombin deficiency or Protein C or S deficiency).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15756, 0, 'Perflutren', 'Cardiovascular Diseases', 'Serious cardiopulmonary reactions including fatalities have uncommonly occurred during or shortly following perflutren- containing microsphere administration, typically within 30 minutes of administration.  The risk may be increased among patients with unstable cardiopulmonary conditions such as acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, or serious ventricular arrhythmias.  Always have cardiopulmonary resuscitation personnel and equipment readily available prior to perflutren administration and monitor all patients for acute reactions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15757, 0, 'Perflutren', 'Hepatic Insufficiency', 'The pharmacokinetics of activated perflutren has not been studied in subjects with hepatic disease.  Caution is advised if used in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15758, 11667, 'Perphenazine', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15759, 28506, 'Perphenazine', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15760, 28507, 'Perphenazine', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15761, 11667, 'Perphenazine', 'Hepatic Insufficiency', 'The manufacturer considers the use of perphenazine to be contraindicated in patients with preexisting liver damage.  Phenothiazines are extensively metabolized by the liver and may accumulate in patients with hepatic impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15762, 28506, 'Perphenazine', 'Hepatic Insufficiency', 'The manufacturer considers the use of perphenazine to be contraindicated in patients with preexisting liver damage.  Phenothiazines are extensively metabolized by the liver and may accumulate in patients with hepatic impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15763, 28507, 'Perphenazine', 'Hepatic Insufficiency', 'The manufacturer considers the use of perphenazine to be contraindicated in patients with preexisting liver damage.  Phenothiazines are extensively metabolized by the liver and may accumulate in patients with hepatic impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15764, 11667, 'Perphenazine', 'Alcoholic Intoxication', 'The use of phenothiazines is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of phenothiazines may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with phenothiazines should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15765, 28506, 'Perphenazine', 'Alcoholic Intoxication', 'The use of phenothiazines is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of phenothiazines may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with phenothiazines should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15766, 28507, 'Perphenazine', 'Alcoholic Intoxication', 'The use of phenothiazines is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of phenothiazines may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with phenothiazines should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15767, 11667, 'Perphenazine', 'Cardiovascular Diseases', 'Phenothiazines may cause hypotension (including orthostatic hypotension), reflex tachycardia, increased pulse rate, syncope, and dizziness, particularly after the first parenteral dose but rarely after the first oral dose.  Low-potency agents such as chlorpromazine and thioridazine are more likely to induce these effects, which usually subside within the first couple of hours following administration.  Tolerance to the hypotensive effects often develops after a few doses.  Rarely, fatal cardiac arrest has occurred secondary to severe hypotension.  Other reported adverse cardiovascular effects include edema, thrombosis, and ECG abnormalities such as PR and QT interval prolongation, diffuse T-wave flattening, and ST segment depression.  Therapy with phenothiazines should be avoided or otherwise administered cautiously in patients with severe cardiovascular disease, pheochromocytoma, a predisposition to hypotension, or conditions that could be exacerbated by hypotension such as a history of myocardial infarction, angina, or ischemic stroke.  Close monitoring of cardiovascular status, including ECG changes, is recommended at all dosages.  If parenteral therapy is given, patients should be in a supine position during administration and for at least 30 to 60 minutes afterwards.  Patients who experience orthostatic hypotension should be cautioned not to rise too abruptly.  Occasionally, when severe, hypotension may require treatment with vasoconstrictive agents such as norepinephrine or phenylephrine.  Epinephrine should not be used, however, since phenothiazines can reverse its vasopressor effects and cause a further lowering of blood pressure.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15768, 28506, 'Perphenazine', 'Cardiovascular Diseases', 'Phenothiazines may cause hypotension (including orthostatic hypotension), reflex tachycardia, increased pulse rate, syncope, and dizziness, particularly after the first parenteral dose but rarely after the first oral dose.  Low-potency agents such as chlorpromazine and thioridazine are more likely to induce these effects, which usually subside within the first couple of hours following administration.  Tolerance to the hypotensive effects often develops after a few doses.  Rarely, fatal cardiac arrest has occurred secondary to severe hypotension.  Other reported adverse cardiovascular effects include edema, thrombosis, and ECG abnormalities such as PR and QT interval prolongation, diffuse T-wave flattening, and ST segment depression.  Therapy with phenothiazines should be avoided or otherwise administered cautiously in patients with severe cardiovascular disease, pheochromocytoma, a predisposition to hypotension, or conditions that could be exacerbated by hypotension such as a history of myocardial infarction, angina, or ischemic stroke.  Close monitoring of cardiovascular status, including ECG changes, is recommended at all dosages.  If parenteral therapy is given, patients should be in a supine position during administration and for at least 30 to 60 minutes afterwards.  Patients who experience orthostatic hypotension should be cautioned not to rise too abruptly.  Occasionally, when severe, hypotension may require treatment with vasoconstrictive agents such as norepinephrine or phenylephrine.  Epinephrine should not be used, however, since phenothiazines can reverse its vasopressor effects and cause a further lowering of blood pressure.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15769, 28507, 'Perphenazine', 'Cardiovascular Diseases', 'Phenothiazines may cause hypotension (including orthostatic hypotension), reflex tachycardia, increased pulse rate, syncope, and dizziness, particularly after the first parenteral dose but rarely after the first oral dose.  Low-potency agents such as chlorpromazine and thioridazine are more likely to induce these effects, which usually subside within the first couple of hours following administration.  Tolerance to the hypotensive effects often develops after a few doses.  Rarely, fatal cardiac arrest has occurred secondary to severe hypotension.  Other reported adverse cardiovascular effects include edema, thrombosis, and ECG abnormalities such as PR and QT interval prolongation, diffuse T-wave flattening, and ST segment depression.  Therapy with phenothiazines should be avoided or otherwise administered cautiously in patients with severe cardiovascular disease, pheochromocytoma, a predisposition to hypotension, or conditions that could be exacerbated by hypotension such as a history of myocardial infarction, angina, or ischemic stroke.  Close monitoring of cardiovascular status, including ECG changes, is recommended at all dosages.  If parenteral therapy is given, patients should be in a supine position during administration and for at least 30 to 60 minutes afterwards.  Patients who experience orthostatic hypotension should be cautioned not to rise too abruptly.  Occasionally, when severe, hypotension may require treatment with vasoconstrictive agents such as norepinephrine or phenylephrine.  Epinephrine should not be used, however, since phenothiazines can reverse its vasopressor effects and cause a further lowering of blood pressure.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15770, 11667, 'Perphenazine', 'Respiratory Insufficiency', 'The use of phenothiazines is contraindicated in comatose patients and patients with severe central nervous system depression.  Phenothiazines may potentiate the CNS and respiratory depression in these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15771, 28506, 'Perphenazine', 'Respiratory Insufficiency', 'The use of phenothiazines is contraindicated in comatose patients and patients with severe central nervous system depression.  Phenothiazines may potentiate the CNS and respiratory depression in these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15772, 28507, 'Perphenazine', 'Respiratory Insufficiency', 'The use of phenothiazines is contraindicated in comatose patients and patients with severe central nervous system depression.  Phenothiazines may potentiate the CNS and respiratory depression in these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15773, 11667, 'Perphenazine', 'Craniocerebral Trauma', 'The use of phenothiazines is contraindicated in patients with suspected or established subcortical brain damage, with or without hypothalamic involvement.  Phenothiazines can interfere with thermoregulatory mechanisms, and a hyperthermic reaction with temperatures in excess of 104 F may occur in such patients, sometimes not until 14 to 16 hours after drug administration.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15774, 28506, 'Perphenazine', 'Craniocerebral Trauma', 'The use of phenothiazines is contraindicated in patients with suspected or established subcortical brain damage, with or without hypothalamic involvement.  Phenothiazines can interfere with thermoregulatory mechanisms, and a hyperthermic reaction with temperatures in excess of 104 F may occur in such patients, sometimes not until 14 to 16 hours after drug administration.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15775, 28507, 'Perphenazine', 'Craniocerebral Trauma', 'The use of phenothiazines is contraindicated in patients with suspected or established subcortical brain damage, with or without hypothalamic involvement.  Phenothiazines can interfere with thermoregulatory mechanisms, and a hyperthermic reaction with temperatures in excess of 104 F may occur in such patients, sometimes not until 14 to 16 hours after drug administration.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15776, 11667, 'Perphenazine', 'Anticholinergic Syndrome', 'Phenothiazines have anticholinergic activity, to which elderly patients are particularly sensitive.  Low-potency agents such as chlorpromazine and thioridazine tend to exhibit greater anticholinergic effects than other agents in the class.  Therapy with phenothiazines should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15777, 28506, 'Perphenazine', 'Anticholinergic Syndrome', 'Phenothiazines have anticholinergic activity, to which elderly patients are particularly sensitive.  Low-potency agents such as chlorpromazine and thioridazine tend to exhibit greater anticholinergic effects than other agents in the class.  Therapy with phenothiazines should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15778, 28507, 'Perphenazine', 'Anticholinergic Syndrome', 'Phenothiazines have anticholinergic activity, to which elderly patients are particularly sensitive.  Low-potency agents such as chlorpromazine and thioridazine tend to exhibit greater anticholinergic effects than other agents in the class.  Therapy with phenothiazines should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15779, 11667, 'Perphenazine', 'Breast Neoplasms', 'The chronic use of phenothiazines is associated with persistent elevations in prolactin levels.  Based on in vitro data, approximately one-third of human breast cancers are thought to be prolactin-dependent.  The clinical significance of this observation is unknown.  Chronic administration of neuroleptic drugs has been associated with mammary tumorigenesis in rodent studies but not in human clinical or epidemiologic studies.  Therapy with phenothiazines should be administered cautiously in patients with existing or suspected malignancy of the breast.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15780, 28506, 'Perphenazine', 'Breast Neoplasms', 'The chronic use of phenothiazines is associated with persistent elevations in prolactin levels.  Based on in vitro data, approximately one-third of human breast cancers are thought to be prolactin-dependent.  The clinical significance of this observation is unknown.  Chronic administration of neuroleptic drugs has been associated with mammary tumorigenesis in rodent studies but not in human clinical or epidemiologic studies.  Therapy with phenothiazines should be administered cautiously in patients with existing or suspected malignancy of the breast.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15781, 28507, 'Perphenazine', 'Breast Neoplasms', 'The chronic use of phenothiazines is associated with persistent elevations in prolactin levels.  Based on in vitro data, approximately one-third of human breast cancers are thought to be prolactin-dependent.  The clinical significance of this observation is unknown.  Chronic administration of neuroleptic drugs has been associated with mammary tumorigenesis in rodent studies but not in human clinical or epidemiologic studies.  Therapy with phenothiazines should be administered cautiously in patients with existing or suspected malignancy of the breast.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15782, 11667, 'Perphenazine', 'Dystonic Disorders', 'Phenothiazines may cause acute, dose-related dystonic reactions secondary to central dopaminergic blockade.  These reactions are characterized by spastic contraction of discrete muscle groups and may include torticollis, opisthotonos, carpopedal spasm, trismus, difficulty swallowing, perioral spasms with protrusion of the tongue, and oculogyric crisis.  Onset is usually within 24 to 96 hours following initiation of therapy or an increase in dosage.  Risk factors include young age, male gender, use of high-potency agents (e.g., fluphenazine, perphenazine, trifluoperazine), high dosages, and IM administration.  Therapy with phenothiazines should be administered cautiously in patients, particularly children, with hypocalcemia or severe dehydration, since these patients may be more susceptible to dystonic reactions.  Most symptoms subside within a few hours and are almost always reversible within 24 to 48 hours following withdrawal of therapy.  However, severe reactions such as laryngospasm may be life-threatening and require appropriate supportive therapy.  Parenteral administration of an anticholinergic antiparkinsonian agent (e.g., benztropine, trihexyphenidyl) or diphenhydramine usually produces a prompt response and may be given orally for short-term maintenance to prevent recurrence of symptoms if phenothiazine therapy must be continued.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15783, 28506, 'Perphenazine', 'Dystonic Disorders', 'Phenothiazines may cause acute, dose-related dystonic reactions secondary to central dopaminergic blockade.  These reactions are characterized by spastic contraction of discrete muscle groups and may include torticollis, opisthotonos, carpopedal spasm, trismus, difficulty swallowing, perioral spasms with protrusion of the tongue, and oculogyric crisis.  Onset is usually within 24 to 96 hours following initiation of therapy or an increase in dosage.  Risk factors include young age, male gender, use of high-potency agents (e.g., fluphenazine, perphenazine, trifluoperazine), high dosages, and IM administration.  Therapy with phenothiazines should be administered cautiously in patients, particularly children, with hypocalcemia or severe dehydration, since these patients may be more susceptible to dystonic reactions.  Most symptoms subside within a few hours and are almost always reversible within 24 to 48 hours following withdrawal of therapy.  However, severe reactions such as laryngospasm may be life-threatening and require appropriate supportive therapy.  Parenteral administration of an anticholinergic antiparkinsonian agent (e.g., benztropine, trihexyphenidyl) or diphenhydramine usually produces a prompt response and may be given orally for short-term maintenance to prevent recurrence of symptoms if phenothiazine therapy must be continued.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15784, 28507, 'Perphenazine', 'Dystonic Disorders', 'Phenothiazines may cause acute, dose-related dystonic reactions secondary to central dopaminergic blockade.  These reactions are characterized by spastic contraction of discrete muscle groups and may include torticollis, opisthotonos, carpopedal spasm, trismus, difficulty swallowing, perioral spasms with protrusion of the tongue, and oculogyric crisis.  Onset is usually within 24 to 96 hours following initiation of therapy or an increase in dosage.  Risk factors include young age, male gender, use of high-potency agents (e.g., fluphenazine, perphenazine, trifluoperazine), high dosages, and IM administration.  Therapy with phenothiazines should be administered cautiously in patients, particularly children, with hypocalcemia or severe dehydration, since these patients may be more susceptible to dystonic reactions.  Most symptoms subside within a few hours and are almost always reversible within 24 to 48 hours following withdrawal of therapy.  However, severe reactions such as laryngospasm may be life-threatening and require appropriate supportive therapy.  Parenteral administration of an anticholinergic antiparkinsonian agent (e.g., benztropine, trihexyphenidyl) or diphenhydramine usually produces a prompt response and may be given orally for short-term maintenance to prevent recurrence of symptoms if phenothiazine therapy must be continued.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15785, 11667, 'Perphenazine', 'Hematologic Diseases', 'Phenothiazines may infrequently cause hematologic toxicity, including agranulocytosis, thrombocytopenia, eosinophilia, aplastic anemia, purpura, granulocytopenia, and hemolytic anemia.  Mild leukopenia may occur frequently with large doses over prolonged periods but is generally reversible despite continued treatment.  Therapy with phenothiazines should be administered cautiously, if at all, in patients with preexisting blood dyscrasias or bone marrow suppression.  Complete blood counts should be obtained regularly, and patients should be instructed to immediately report any signs or symptoms suggestive of blood dyscrasia such as fever, sore throat, local infection, bleeding, pallor, dizziness, or jaundice.  Most cases of agranulocytosis have occurred between the fourth and tenth weeks of therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15786, 28506, 'Perphenazine', 'Hematologic Diseases', 'Phenothiazines may infrequently cause hematologic toxicity, including agranulocytosis, thrombocytopenia, eosinophilia, aplastic anemia, purpura, granulocytopenia, and hemolytic anemia.  Mild leukopenia may occur frequently with large doses over prolonged periods but is generally reversible despite continued treatment.  Therapy with phenothiazines should be administered cautiously, if at all, in patients with preexisting blood dyscrasias or bone marrow suppression.  Complete blood counts should be obtained regularly, and patients should be instructed to immediately report any signs or symptoms suggestive of blood dyscrasia such as fever, sore throat, local infection, bleeding, pallor, dizziness, or jaundice.  Most cases of agranulocytosis have occurred between the fourth and tenth weeks of therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15787, 28507, 'Perphenazine', 'Hematologic Diseases', 'Phenothiazines may infrequently cause hematologic toxicity, including agranulocytosis, thrombocytopenia, eosinophilia, aplastic anemia, purpura, granulocytopenia, and hemolytic anemia.  Mild leukopenia may occur frequently with large doses over prolonged periods but is generally reversible despite continued treatment.  Therapy with phenothiazines should be administered cautiously, if at all, in patients with preexisting blood dyscrasias or bone marrow suppression.  Complete blood counts should be obtained regularly, and patients should be instructed to immediately report any signs or symptoms suggestive of blood dyscrasia such as fever, sore throat, local infection, bleeding, pallor, dizziness, or jaundice.  Most cases of agranulocytosis have occurred between the fourth and tenth weeks of therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15788, 11667, 'Perphenazine', 'Neuroleptic Malignant Syndrome', 'The central dopaminergic blocking effects of phenothiazines may precipitate or aggravate a potentially fatal symptom complex known as Neuroleptic Malignant Syndrome (NMS).  NMS is observed most frequently when high-potency neuroleptic agents like haloperidol or fluphenazine are administered intramuscularly but may occur with any agent possessing neuroleptic activity given for any length of time.  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Phenothiazine therapy should not be initiated in patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of phenothiazines should be carefully considered, since NMS may recur.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15789, 28506, 'Perphenazine', 'Neuroleptic Malignant Syndrome', 'The central dopaminergic blocking effects of phenothiazines may precipitate or aggravate a potentially fatal symptom complex known as Neuroleptic Malignant Syndrome (NMS).  NMS is observed most frequently when high-potency neuroleptic agents like haloperidol or fluphenazine are administered intramuscularly but may occur with any agent possessing neuroleptic activity given for any length of time.  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Phenothiazine therapy should not be initiated in patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of phenothiazines should be carefully considered, since NMS may recur.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15790, 28507, 'Perphenazine', 'Neuroleptic Malignant Syndrome', 'The central dopaminergic blocking effects of phenothiazines may precipitate or aggravate a potentially fatal symptom complex known as Neuroleptic Malignant Syndrome (NMS).  NMS is observed most frequently when high-potency neuroleptic agents like haloperidol or fluphenazine are administered intramuscularly but may occur with any agent possessing neuroleptic activity given for any length of time.  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Phenothiazine therapy should not be initiated in patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of phenothiazines should be carefully considered, since NMS may recur.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15791, 11667, 'Perphenazine', 'Parkinsonian Disorders', 'The use of phenothiazines is associated with pseudo-parkinsonian symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually 1 to 2 weeks following initiation of therapy or an increase in dosage.  Propylamino derivatives such as chlorpromazine, promazine, and triflupromazine may be more likely to induce these effects.  Therapy with phenothiazines should be administered cautiously in patients with Parkinson''s disease or parkinsonian symptoms.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15792, 28506, 'Perphenazine', 'Parkinsonian Disorders', 'The use of phenothiazines is associated with pseudo-parkinsonian symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually 1 to 2 weeks following initiation of therapy or an increase in dosage.  Propylamino derivatives such as chlorpromazine, promazine, and triflupromazine may be more likely to induce these effects.  Therapy with phenothiazines should be administered cautiously in patients with Parkinson''s disease or parkinsonian symptoms.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15793, 28507, 'Perphenazine', 'Parkinsonian Disorders', 'The use of phenothiazines is associated with pseudo-parkinsonian symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually 1 to 2 weeks following initiation of therapy or an increase in dosage.  Propylamino derivatives such as chlorpromazine, promazine, and triflupromazine may be more likely to induce these effects.  Therapy with phenothiazines should be administered cautiously in patients with Parkinson''s disease or parkinsonian symptoms.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15794, 11667, 'Perphenazine', 'Kidney Diseases', 'Phenothiazines and their metabolites are excreted by the kidney.  There are very limited data concerning the use of phenothiazines in patients with renal disease.  Therapy with phenothiazines should be administered cautiously in patients with significantly impaired renal function.  The manufacturers recommend periodic renal function tests for all patients during prolonged therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15795, 28506, 'Perphenazine', 'Kidney Diseases', 'Phenothiazines and their metabolites are excreted by the kidney.  There are very limited data concerning the use of phenothiazines in patients with renal disease.  Therapy with phenothiazines should be administered cautiously in patients with significantly impaired renal function.  The manufacturers recommend periodic renal function tests for all patients during prolonged therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15796, 28507, 'Perphenazine', 'Kidney Diseases', 'Phenothiazines and their metabolites are excreted by the kidney.  There are very limited data concerning the use of phenothiazines in patients with renal disease.  Therapy with phenothiazines should be administered cautiously in patients with significantly impaired renal function.  The manufacturers recommend periodic renal function tests for all patients during prolonged therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15797, 11667, 'Perphenazine', 'Lung Diseases', 'Phenothiazines may suppress the cough reflex.  Therapy with phenothiazines should be administered cautiously in patients with chronic respiratory disorders, including severe asthma, emphysema, or acute respiratory tract infections.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15798, 28506, 'Perphenazine', 'Lung Diseases', 'Phenothiazines may suppress the cough reflex.  Therapy with phenothiazines should be administered cautiously in patients with chronic respiratory disorders, including severe asthma, emphysema, or acute respiratory tract infections.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15799, 28507, 'Perphenazine', 'Lung Diseases', 'Phenothiazines may suppress the cough reflex.  Therapy with phenothiazines should be administered cautiously in patients with chronic respiratory disorders, including severe asthma, emphysema, or acute respiratory tract infections.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15800, 11667, 'Perphenazine', 'Epilepsy', 'Phenothiazines can lower the seizure threshold and induce seizures, particularly when dosages are high or increased rapidly and during the initiation of therapy.  Of the phenothiazines used in the treatment of psychosis, chlorpromazine appears to have the greatest epileptogenic potential, while fluphenazine and thioridazine have the least.  Therapy with phenothiazines should be administered cautiously in patients with a history of seizures or other factors predisposing to seizures such as abnormal EEG, preexisting CNS pathology, or head trauma.  Adequate anticonvulsant therapy should be maintained during administration of phenothiazines.', '2', '', 'DDInter', 0);
